Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Place your right palm on the bench
There was no difference between the groups in the number of procedural complications or adverse events
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
DOI: 10.1089/ars.2017.7051 93
US$ 20.39
US$ 22.33
US$ 29.67
US$ 20.98
US$ 26.18
US$ 25.22
US$ 25.32
